Search

Your search keyword '"TAMBONE REYES, M"' showing total 11 results
Start Over Author "TAMBONE REYES, M" Language english
11 results on '"TAMBONE REYES, M"'

2. Epidemiology of acute promyelocytic leukemia in Italy

Author

Rotoli, B., De Rosa, G., Papa, G., Venditti, A., Citarrella, P., Tambone Reyes, M., Ascari, E., Invernizzi, R., Cajozzo, A., Musso, M., Alberti, A., Peta, A., Rossi Ferrini, P., Leoni, F., Caronia, F., Mirto, S., Nobile, F., Iacopino, P., Resegotti, L., Allione, B., Monfardini, S., Zagonel, V., Liso, V., Specchia, G., Tura, S., Visani, G., Broccia, G., Deplano, W., Ricciuti, F., Pizzuti, M., Longinotti, M., Bonfigli, S., De Laurenzi, A., Pacilli, L., Deriu, L., Chierichini, A., Bizzi, B., Leone, G., De Biasi, R., Miraglia, E., Bruzzese, L., Abbadessa, A., Avvisati, G., Mele, A., Stazi, M.A., Vegna, M.L., Pasquini, P., and Mandelli, F.

Published
1991
Full Text
View/download PDF

4. Biologic relevance of elevated red cell adenosine deaminase activity in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria.

Author

di Marco P, Tinnirello D, Tambone-Reyes M, Tedesco L, Luna S, and Citarella P

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Preleukemia enzymology, Adenosine Deaminase blood, Erythrocytes enzymology, Hemoglobinuria, Paroxysmal enzymology, Myelodysplastic Syndromes enzymology
Abstract

Red cell adenosine deaminase (ADA-RBC) activity in patients with myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria is significantly increased compared to that observed in normal controls. ADA-RBC activity is not related to fetal hemoglobin concentration, but it is significantly correlated with hemoglobin concentration at diagnosis and with the degree of morphologic dysplasia in the erythroid lineage. The results of our study suggest that the observed enzymatic abnormality may constitute a non-specific manifestation of the stem cell alteration that determines these disorders.

Published
1992
Full Text
View/download PDF

5. Cyclophosphamide plus vincristine and prednisone in the treatment of severe pemphigus vulgaris refractory to conventional therapy.

Author

Citarrella P, Gebbia V, Di Marco P, Tambone Reyes M, Noto G, and Aricò M

Subjects
Adolescent, Aged, Cyclophosphamide adverse effects, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Prednisone adverse effects, Vincristine adverse effects, Cyclophosphamide therapeutic use, Pemphigus drug therapy, Prednisone therapeutic use, Vincristine therapeutic use
Abstract

Five patients with severe pemphigus vulgaris refractory to conventional therapy with azathioprine and corticosteroids were treated with cyclophosphamide, vincristine and prednisone. One patient was not evaluable, while the remaining four patients showed a complete response. Duration of response was in the range of 13-94 months. Toxicity was mainly represented by alopecia, myelosuppression and gastrointestinal side-effects such as nausea/vomiting. Although cyclophosphamide and vincristine may induce severe side-effects, this association may be useful in controlling severe disease resistant to previous conventional therapies.

Published
1992
Full Text
View/download PDF

6. Thymopentin (TP 5) in the management of patients with uremia.

Author

Bonaccorso R, Gebbia V, Tambone Reyes M, Pappalardo MS, Peralta S, La Iuppa M, Teresi M, Di Marco P, Citarrella P, and Mansueto S

Subjects
Controlled Clinical Trials as Topic, Humans, Leukocyte Count, Reference Values, T-Lymphocyte Subsets drug effects, T-Lymphocyte Subsets immunology, Uremia immunology, Adjuvants, Immunologic therapeutic use, Thymopentin therapeutic use, Uremia drug therapy
Published
1989

7. Treatment of polycythemia vera with hydroxyurea.

Author

Gebbia V, Bonaccorso R, Tambone Reyes M, Di Salvo V, Di Marco P, and Citarrella P

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Polycythemia Vera, Treatment Outcome, Antisickling Agents therapeutic use, Hydroxyurea therapeutic use
Published
1989

8. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.

Author

Tambone Reyes M, Bonaccorso R, Gebbia V, Tinnirello D, Di Salvo V, Ciulla A, Di Marco P, Mansueto S, and Citarrella P

Subjects
Aged, Aged, 80 and over, Anemia, Refractory, with Excess of Blasts drug therapy, Antimetabolites, Antineoplastic administration & dosage, Cytarabine administration & dosage, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Treatment Outcome, Antimetabolites, Antineoplastic therapeutic use, Cytarabine therapeutic use, Leukemia, Myeloid, Acute drug therapy, Myelodysplastic Syndromes drug therapy
Published
1989

9. Recombinant alpha 2 interferon in the treatment of chronic myeloproliferative disorders.

Author

Bonaccorso R, Teresi M, Gebbia V, Tambone Reyes M, Tinnirello D, Di Marco P, Citarrella P, and Mansueto S

Subjects
Adult, Aged, Chronic Disease, Female, Humans, Interferon alpha-2, Male, Middle Aged, Myeloproliferative Disorders blood, Platelet Aggregation drug effects, Primary Myelofibrosis drug therapy, Recombinant Proteins, Thrombocythemia, Essential drug therapy, Treatment Outcome, Antineoplastic Agents therapeutic use, Interferon-alpha therapeutic use, Myeloproliferative Disorders drug therapy
Published
1989

11. Alpha interferon in the treatment of hairy cell leukemia.

Author

Tambone Reyes M, Gebbia V, Teresi M, Bonaccorso R, Colucci A, Quartararo L, Di Marco P, Citarrella P, and Mansueto S

Subjects
Aged, Blood Transfusion, Bone Marrow drug effects, Bone Marrow pathology, Female, Humans, Leukemia, Hairy Cell blood, Leukemia, Hairy Cell pathology, Male, Middle Aged, Treatment Outcome, Antineoplastic Agents therapeutic use, Interferon-alpha therapeutic use, Leukemia, Hairy Cell drug therapy
Published
1989

Catalog

Books, media, physical & digital resources
See catalog results